ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2976

Disease Flares and Persistent Low-Level of Disease: Long-Term Outcome in a Cohort of Patients with BehçEt’s Disease

Elena Elefante1, Rosaria Talarico1, Anna d'Ascanio2, Rossella Neri1, Chiara Stagnaro2, Chiara Tani2, Chiara Baldini2 and Marta Mosca2, 1RHEUMATOLOGY UNIT, University of Pisa, Pisa, Italy, 2Rheumatology Unit, University of Pisa, Pisa, Italy

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Behcet's syndrome and outcomes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Vasculitis - Poster III: Rarer Vasculitides

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Behçet’s disease (BD) is a multisystemic, chronic relapsing inflammatory disease classified among the vasculitis. Neurological and eye involvement are two of the most serious manifestation of BD and both still represent significant causes of morbidity. The primary aim of the study was to evaluate the long-term outcome in a cohort of patents with BD; the secondary aim was to explore any potential correlation between long-term outcome and demographic and clinical profile.

Methods:  The study enrolled 122 patients, all fulfilling the International Study Group (ISG) criteria for BD. The male/female ratio was 1.6:1, with a mean disease duration of 11±4 years. Their mean age was 42±9 years (min:18, max:77), while the mean age at disease onset was 25±4 years. The mean ± SD duration of follow-up at our centre was 10±2 years. Long-term outcome was evaluated by means of disease flares according the BD Current Activity Form (BDCAF), persistent low-level of disease (defined as a level minimal activity of disease requiring only low-medium doses of corticosteroids), and disease damage according the Vasculitis Damage Index (VDI). The statistical analysis was performed using Student t-test, Mann-Whitney-U test, ANOVA and Pearson correlation

Results: The main clinical features presented during the follow-up by the cohort were: mucocutaneous involvement (100%), joint involvement (49%), ocular involvement (40%), neurological involvement (38%), vascular thrombotic events (22%), gastro-enteric involvement (16%). Globally, we observed 108 episodes of disease flare, of which: 25% of patients with neurological involvement, 60% of ocular involvement, 50% of muco-cutaneous involvement, 12% of joint involvement, 50% of vascular involvement and 28% of gastro-enteric involvement. Thirty-four patients presented a persistent low-level disease, that required a medium corticosteroids dose of 4 mg of 6-methylprednisolone. Moreover, 39 patients presented a VDI > 1. A significant correlation was found between disease flares and younger age and male sex; persistent low-level of disease and disease damage resulted significantly associated with early onset of disease and high number of disease flare in the first 2 years of disease. Notably, persistent low-level of disease and disease damage resulted inversely correlated with the use of anti TNF alpha agents, independently of the type of organ involvement.

Conclusion: As literature data suggest, a specific demographic profile exists of poor outcome in BD, represented by young males. The use of anti TNF alpha agents is associated with a positive effect on maintaining remission of disease, most likely due to their steroid sparing effect.


Disclosure: E. Elefante, None; R. Talarico, None; A. d'Ascanio, None; R. Neri, None; C. Stagnaro, None; C. Tani, None; C. Baldini, None; M. Mosca, None.

To cite this abstract in AMA style:

Elefante E, Talarico R, d'Ascanio A, Neri R, Stagnaro C, Tani C, Baldini C, Mosca M. Disease Flares and Persistent Low-Level of Disease: Long-Term Outcome in a Cohort of Patients with BehçEt’s Disease [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/disease-flares-and-persistent-low-level-of-disease-long-term-outcome-in-a-cohort-of-patients-with-behcets-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-flares-and-persistent-low-level-of-disease-long-term-outcome-in-a-cohort-of-patients-with-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology